A carregar...
Bcl-2 expression in rituximab refractory cutaneous B-cell lymphoma
Rituximab has been established as an effective and safe therapy for cutaneous B-cell lymphoma (CBCL). Different survival pathways, that is the Raf/MEK/Erk- or the p38MAPK cascade, have been suggested as downstream mediators of rituximab and may be involved in treatment failure. Biopsies from four pa...
Na minha lista:
| Main Authors: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group
2007
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2359948/ https://ncbi.nlm.nih.gov/pubmed/17473827 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6603762 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|